

Online supplement for Safety and Efficacy of SBI-087, a Subcutaneous Agent for B Cell Depletion, in Patients with Active Rheumatoid Arthritis: Results from a Phase II Randomized, Double-blind, Placebo-controlled Study. *The Journal of Rheumatology*. doi:10.3899/jrheum.160146

Supplementary Figure 1. Study design and treatment regimens. RA: rheumatoid arthritis; SBI: SBI-087; Pbo: placebo. SBI/SBI/Pbo = 200 mg SBI-087 on days 1 and 5. SBI/Pbo/SBI = 200 mg SBI-087 on Day 1 and in Week 12. SBI/SBI/SBI = 200 mg SBI-087 on days 1 and 15, and in Week 12.

